Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 15;202(8):1133–1145. doi: 10.1164/rccm.202001-0180OC

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 by the American Thoracic Society

This article is open access and distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Figure 4. — Effect of rhAC (recombinant human acid ceramidase) treatment on the ceramide and sphingosine profile of cystic fibrosis (CF) and non-CF airway epithelial cell cultures. (A and B) Levels of total ceramide (A) and sphingosine (B) from whole-cell lysates of CF and non-CF cultures at baseline and after treatment with rhAC. (C) Individual ceramide species, displayed as radar charts (fmol/mg protein). (D and E) Plasma membrane (PM) fractions of total ceramide (D) and sphingosine (E) in CF and non-CF cultures at baseline and after treatment with rhAC. (F) Individual ceramide species, displayed as radar charts (fmol/mg protein). (G and H) Proportion of ceramide in PMs (as a fraction of total cellular ceramide) (G) and the equivalent for sphingosine (H). Throughout, n = 6 separate experiments from individual donors. Cultures were lysed and fractionated into whole-cell and plasma membrane fractions after 28 days at air–liquid interface and full differentiation. Individual data points are presented along with the mean (horizontal line) ± SD (error bars). For statistical tests used, see the online supplement. *P < 0.05 and **P ≤ 0.01.